This is a Phase III, double-blind, placebo-controlled, safety and efficacy study of daily SC metreleptin in subjects with Partial Lipodystrophy.
Partial Lipodystrophy
This is a Phase III, double-blind, placebo-controlled, safety and efficacy study of daily SC metreleptin in subjects with Partial Lipodystrophy.
Study to Evaluate the Safety and Efficacy of Daily Subcutaneous Metreleptin Treatment in Subjects With PL
-
Amryt Research Site, University of Alabama, Birmingham, Alabama, United States, 35233
Massachusetts General Hospital, Boston, Massachusetts, United States, 02114
Amryt Research Site, University of Michigan, Ann Arbor, Michigan, United States, 48109
Amryt Research Site, Mayo Clinic,, Rochester, Minnesota, United States, 55902
Amryt Research Site, University of Missouri, Columbia, Missouri, United States, 65212
Amryt Research Site, Endocrinology Research Associates Inc, Columbus, Ohio, United States, 43201
Amryt Research Site, The Ohio State University Wexner Medical Center, Columbus, Ohio, United States, 43210
Amryt Research Site, University of Pennsylvania, Philadelphia, Pennsylvania, United States, 19104
Amryt Research Site, UT Southwestern Medical Center, Dallas, Texas, United States, 75390
Amryt Research Site, Medical College of Wisconsin, Milwaukee, Wisconsin, United States, 53226
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
12 Years to
ALL
No
Amryt Pharma,
2026-01-31